Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation

被引:1
|
作者
Migliori, GB
Khomenko, AG
Punga, VV
Ambrosetti, M
Danilova, I
Ribka, LN
Grzemska, M
Sawert, H
Raviglione, MC
机构
[1] Fdn Salvatore Maugeri, Clin Lavoro Riabilitaz, Care & Res Inst, I-21049 Tradate, Italy
[2] Cent TB Res Inst, Moscow, Russia
[3] Ivanovo TB Dispensary, Ivanovo, Russia
[4] WHO, Global TB Programme, CH-1211 Geneva, Switzerland
[5] WHO, Country Off, Nonthaburi, Thailand
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Many of the current tuberculosis control programmes in the Russian Federation are based on costly strategies which are underfunded and use long, individualized treatment regimens. This article compares, using a cost-effectiveness analysis, the new WHO strategy implemented in the Ivanovo Oblast (case-finding among symptomatic patients (SCF) and shorter regimens) and the old strategy (active screening of the asymptomatic population (ACF) and longer regimens). The cost per case cured was calculated at different levels of cure rate (45-95%) using three scenarios to describe the new WHO strategy (use of WHO-recommended regimens and three options at increasing rates of admission) and a fourth scenario to describe the old strategy tall patients admitted for the whole treatment and longer regimens). The cost per case detected was determined by calculating the following: yield of the new and old strategy (number of examinations necessary to diagnose one case); cost of the diagnostic process; multiplying yield per cost according to the three scenarios describing the new WHO strategy and a fourth scenario describing the old strategy. In the Ivanovo Oblast the cost per case cured, at 85% cure rate level, ranged from US% 1197 (new strategy, scenario I without food) to US$ 6293 told strategy, scenario 4) the cost per case detected ranged from US$ 1581 (new strategy, scenario I) to US$ 4000 told strategy scenario 4). Significant savings can result from shifting towards the new WHO strategy. Decision-makers and health administrators should be responsible for re-investing the financial and human resources mobilized by the adoption of cost-effective strategies within the TB control programme.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 50 条
  • [41] Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
    Haukaas, Fredrik Salvesen
    Arnesen, Trude Margrete
    Winje, Brita Askeland
    Aas, Eline
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (04): : 405 - 415
  • [42] Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis
    Luciene C Scherer
    Rosa D Sperhacke
    Antonio Ruffino-Netto
    Maria LR Rossetti
    Claudia Vater
    Paul Klatser
    Afrânio L Kritski
    BMC Infectious Diseases, 9
  • [43] Tuberculosis in Ethiopia: Optimal Intervention Strategies and Cost-Effectiveness Analysis
    Mengistu, Ashenafi Kelemu
    Witbooi, Peter J.
    AXIOMS, 2022, 11 (07)
  • [44] Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis
    Scherer, Luciene C.
    Sperhacke, Rosa D.
    Ruffino-Netto, Antonio
    Rossetti, Maria L. R.
    Vater, Claudia
    Klatser, Paul
    Kritski, Afranio L.
    BMC INFECTIOUS DISEASES, 2009, 9
  • [45] Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
    Fredrik Salvesen Haukaas
    Trude Margrete Arnesen
    Brita Askeland Winje
    Eline Aas
    The European Journal of Health Economics, 2017, 18 : 405 - 415
  • [46] COST - EFFECTIVENESS ANALYSIS OF VILANTEROL/FLUTICASONE FUROATE FOR ASTHMA TREATMENT IN THE RUSSIAN FEDERATION
    Makarova, E.
    Yagudina, R.
    Kulikov, A.
    VALUE IN HEALTH, 2018, 21 : S412 - S412
  • [47] COST-EFFECTIVENESS ANALYSIS OF THE PRIMOVACCINATION OF NEWBORNS AGAINST TUBERCULOSIS IN SLOVAKIA
    Marusakova, E.
    Bielik, J.
    Frecerova, K.
    Nevicka, E.
    Sedlakova, D.
    VALUE IN HEALTH, 2012, 15 (07) : A393 - A393
  • [48] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    G. B. Gomez
    D. W. Dowdy
    M. L. Bastos
    A. Zwerling
    S. Sweeney
    N. Foster
    A. Trajman
    M. A. Islam
    S. Kapiga
    E. Sinanovic
    G. M. Knight
    R. G. White
    W. A. Wells
    F. G. Cobelens
    A. Vassall
    BMC Infectious Diseases, 16
  • [49] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    Gomez, G. B.
    Dowdy, D. W.
    Bastos, M. L.
    Zwerling, A.
    Sweeney, S.
    Foster, N.
    Trajman, A.
    Islam, M. A.
    Kapiga, S.
    Sinanovic, E.
    Knight, G. M.
    White, R. G.
    Wells, W. A.
    Cobelens, F. G.
    Vassall, A.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [50] Tuberculosis control priorities defined by using cost-effectiveness and burden of disease
    Xu, Q
    Wu, ZL
    Jin, SG
    Zhang, LX
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2002, 15 (02) : 172 - 176